<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00292825</url>
  </required_header>
  <id_info>
    <org_study_id>skejbyH</org_study_id>
    <nct_id>NCT00292825</nct_id>
  </id_info>
  <brief_title>Effect of Closed Loop Pacemaker Treatment on Recurrent Vasovagal Syncope</brief_title>
  <official_title>SCANdinavian Vasovagal SYNCope Pacemaker Investigation (SCANSYNC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital Skejby</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biotronik SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital Skejby</source>
  <brief_summary>
    <textblock>
      The main purpose is to prevent syncope in patients with recurrent syncopal episodes caused by&#xD;
      malignant vasovagal faints and bradycardia. Patients are treated by a special pacemaker&#xD;
      (closed loop stimulation [CLS]) which can potentially identify an incipient attack and&#xD;
      prevent syncope by pacing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment of patients with recurrent syncope of vasovagal origin, not precipitated by&#xD;
      usual vasovagal factors, and not associated with structural heart disease, is unsolved. The&#xD;
      limitations of the conducted 5 pacemaker studies are a significant placebo effect of&#xD;
      pacemaker treatment, underpowering and lack of double blinding. The pacemaker intervention&#xD;
      has been accelerated dual chamber pacing at the time of bradycardia, which may be too late.&#xD;
      However, a pooling of all data indicate a beneficial effect of pacing.&#xD;
&#xD;
      Vasodilatation is an obligate element of all vasovagal syncopal episodes and in many also an&#xD;
      early sign associated with the hyperkinetic empty left ventricle which triggers the reflex&#xD;
      wave. The principle in closed loop stimulation (CLS) is a continuous surveillance of the&#xD;
      impedance in the right ventricle which correlates highly with myocardial contractility. When&#xD;
      contractility is increased significantly atrial pacing with prolonged AV delay is commenced.&#xD;
      This principle has been used in chronotropic incompetent patients and in one small study of&#xD;
      patients with vasovagal syncope with a positive outcome. The hypothesis is that the CLS will&#xD;
      potentially identify an incipient vasovagal attack and be able to prevent the drop in cardiac&#xD;
      output and bradycardia by early accelerated pacing.&#xD;
&#xD;
      Patients will be treated 12 months with active pacing (CLS) and then crossed over to 12&#xD;
      months with passive pacing (VVI, 30 bpm).&#xD;
&#xD;
      The study will be double blinded, only a technician will know the status of the pacemaker.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of syncope, active (CLS pacing) versus passive (VVI=30) pacing period</measure>
    <time_frame>12 months + 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of syncopal and presyncopal episodes, active versus passive pacing period</measure>
    <time_frame>12 months+12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life, active versus passive pacing period</measure>
    <time_frame>12 months+12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Vasovagal Syncope</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pacemaker treatment, pacemaker programmed as active = CLS</intervention_name>
    <description>Pacemaker treatment with closed loop function(CLS)</description>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pacemaker, programmed as passive = VVI 30 beats per minute (bpm)</intervention_name>
    <description>pacemaker treatment as VVI 30 bpm</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A clinical problem with vasovagal syncope which motivates considerations concerning&#xD;
             pacemaker treatment.&#xD;
&#xD;
          -  A positive tilt-table test.&#xD;
&#xD;
          -  Exclusion of other causes for syncope by a complete diagnostic work-up allowing only&#xD;
             minor cardiac abnormalities&#xD;
&#xD;
          -  Syncope for &gt;= 2 years.&#xD;
&#xD;
          -  Number of syncopal episodes &gt;= 3&#xD;
&#xD;
          -  At least 1 instance of syncope within the last 6 months.&#xD;
&#xD;
          -  A positive tilt-table test which reproduces the clinical syncope and is associated&#xD;
             with a clearly abnormal haemodynamic response:&#xD;
&#xD;
               -  Vasovagal Syncope International Study (VASIS) type 1 with bradycardia &lt; 40 bpm,&#xD;
                  or&#xD;
&#xD;
               -  VASIS type 2A, or&#xD;
&#xD;
               -  VASIS type 2B&#xD;
&#xD;
          -  Stable clinical condition&#xD;
&#xD;
          -  Able to accept and follow the protocol and give written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Conventional indication for pacemaker (i.e. atrioventricular [AV] block)&#xD;
&#xD;
          -  Indication for cardiac resynchronisation therapy (i.e. left bundle branch block&#xD;
             [LBBB])&#xD;
&#xD;
          -  Documented atrial fibrillation or flutter&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  History of myocardial infarction (MI) or angina pectoris&#xD;
&#xD;
          -  Serious chronic disease, life expectancy &lt; 3 years.&#xD;
&#xD;
          -  Age &lt; 25 years&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
&#xD;
          -  Participating in other investigation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Mølgaard, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Skejby Sygehus, Aarhus University Hospital, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henning Mølgaard, MD, DMSc</name>
      <address>
        <city>Århus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>February 15, 2006</study_first_submitted>
  <study_first_submitted_qc>February 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2006</study_first_posted>
  <last_update_submitted>March 31, 2010</last_update_submitted>
  <last_update_submitted_qc>March 31, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Henning Mølgaard M.D., DMSc</name_title>
    <organization>Aarhus University Hospital, Skejby; Århus, Denmark</organization>
  </responsible_party>
  <keyword>vasovagal syncope</keyword>
  <keyword>syncope</keyword>
  <keyword>cardioinhibitory syncope</keyword>
  <keyword>neurocardiogenic syncope</keyword>
  <keyword>pacing</keyword>
  <keyword>closed loop pacing</keyword>
  <keyword>tilt table</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syncope</mesh_term>
    <mesh_term>Syncope, Vasovagal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

